SELLAS Life Sciences Group, Inc. Cash and Restricted Cash
SELLAS Life Sciences Group, Inc. (SLS) had Cash and Restricted Cash of $138.44 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $138.44M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $107.20M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $71.89M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $44.42M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $138.44M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $107.20M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $71.89M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $44.42M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $25.40M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $28.50M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $13.99M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $21.13M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $9.25M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $18.52M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $2.63M 10-K · filed 2026-03-19 | |
| 2023-09-30 | $4.07M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $13.91M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $24.00M 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $17.23M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $21.45M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $27.09M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $14.35M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $21.45M 10-K · filed 2024-03-28 | |
| 2021-09-30 | $26.38M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $30.02M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $28.13M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $35.40M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $8.30M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $3.44M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $6.85M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $7.38M 10-K · filed 2022-03-31 | |
| 2019-09-30 | $9.23M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $12.87M 10-Q · filed 2020-08-13 | |
| 2019-03-31 | $2.69M 10-Q · filed 2020-05-14 | |
| 2018-12-31 | $5.45M 10-K · filed 2021-03-23 | |
| 2018-09-30 | $10.08M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $9.99M 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $12.09M 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $12.75M 10-K · filed 2020-03-13 | |
| 2017-09-30 | $2.37M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $4.76M 10-Q · filed 2018-08-14 | |
| 2017-03-31 | $2.16M 10-Q · filed 2018-05-15 | |
| 2016-12-31 | $6.05M 10-K · filed 2019-03-22 | $5.96M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |